Spray-Dried Solid Dispersion for Macrocyclic Compound Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Macrocyclic compounds effective against HCV infection face limitations due to poor pharmacological properties such as low solubility and bioavailability, restricting their therapeutic potential.
Innovation Solution
A spray-dried solid dispersion is developed, incorporating a pharmaceutically acceptable polymer like poloxamer, polyvinylpyrrolidone, or hydroxypropylcellulose, which enhances the solubility and bioavailability of macrocyclic compounds by dispersing them in a polymer matrix, with a weight ratio of 4:1 to 1:4, improving their pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If macrocyclic compounds are used to inhibit HCV NS3/4A protease activity, then antiviral efficacy is improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent creates a composite material system consisting of macrocyclic compounds combined with hydrophilic polymers (such as polyethylene glycol, polyvinylpyrrolidone, or hydroxypropyl cellulose) to form solid dispersions. This composite approach allows the hydrophobic macrocyclic compound to be dispersed within a hydrophilic polymer matrix, dramatically improving solubility while maintaining the compound's antiviral activity against HCV NS3/4A protease.
Solution Approach 2:
The patent changes the physical state and dispersion parameters of the macrocyclic compound by converting it from a pure crystalline form to an amorphous dispersed state within a polymer matrix. This parameter change from crystalline to amorphous form, along with controlling the polymer-to-compound ratio, significantly enhances solubility and bioavailability while preserving therapeutic efficacy.
2Reliability
If macrocyclic compounds are used to inhibit HCV NS3/4A protease activity, then antiviral efficacy is improved, but bioavailability deteriorates
Solution Approach 1:
The solid dispersion composite combines the macrocyclic compound with hydrophilic polymers to create a formulation that improves dissolution and absorption characteristics. The polymer matrix facilitates better interaction with biological fluids, enhancing bioavailability while maintaining the compound's ability to inhibit HCV NS3/4A protease.
Solution Approach 2:
By changing the physical form from pure compound to dispersed state in a polymer matrix, and by controlling particle size and surface area through the spray-drying process, the patent improves bioavailability. The amorphous state and increased surface area enhance dissolution rate and extent, leading to improved systemic absorption.
3Quantity of substance
If spray-dried solid dispersion is prepared with polymer matrix, then solubility is improved, but formulation complexity increases
Solution Approach 1:
The hydrophilic polymer acts as an intermediary substance that mediates between the hydrophobic macrocyclic compound and the aqueous environment. This intermediary polymer matrix simplifies the overall formulation approach by providing a pre-established solubilizing environment, eliminating the need for complex co-solvent systems or surfactant combinations.
Solution Approach 2:
The spray-drying process parameters (inlet temperature, outlet temperature, feed rate, atomization pressure) are optimized to create the solid dispersion in a single step. By controlling these parameters, the patent achieves both solubility improvement and process simplification, as the entire formulation is created in one operation rather than requiring multiple processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The spray-dried solid dispersion exhibits high solubility and bioavailability, leading to improved dissolution performance, disintegration time, and drug release profiles, effectively addressing the limitations of macrocyclic compounds in treating HCV infection.
Implementation Method 1
the pharmaceutical compound or its salt is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer
Implementation Method 2
spray-dried solid dispersion
Data Source
AI summary
A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer,in which the pharmaceutical compound is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing such a solid dispersion and using it for treating hepatitis C virus infection and a pharmaceutical formulation containing same.